Literature DB >> 31097982

CBD: A New Hope?

Paula Morales1, Patricia H Reggio2.   

Abstract

The nonpsychoactive phytocannabinoid, CBD, was recently approved by the Food and Drug Administration for the treatment of children with drug-resistant epilepsy. This milestone opens new avenues for cannabinoid research. In this Viewpoint, we provide an overview of recent progress in the field highlighting molecular insights into CBD's mechanism of action, as well as its therapeutic potential.

Entities:  

Year:  2019        PMID： 31097982      PMCID： PMC6511966          DOI： 10.1021/acsmedchemlett.9b00127

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


  11 in total

Review 1.  Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences.

Authors:  J M McPartland; M Glass; R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-07-16       Impact factor: 8.739

Review 2.  Cannabinoid therapy in epilepsy.

Authors:  Santoshi Billakota; Orrin Devinsky; Eric Marsh
Journal:  Curr Opin Neurol       Date:  2019-04       Impact factor: 5.710

3.  Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.

Authors:  A Thomas; G L Baillie; A M Phillips; R K Razdan; R A Ross; R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-01-22       Impact factor: 8.739

4.  Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors.

Authors:  Mylyne Tham; Orhan Yilmaz; Mariam Alaverdashvili; Melanie E M Kelly; Eileen M Denovan-Wright; Robert B Laprairie
Journal:  Br J Pharmacol       Date:  2018-08-10       Impact factor: 8.739

Review 5.  Molecular Targets of the Phytocannabinoids: A Complex Picture.

Authors:  Paula Morales; Dow P Hurst; Patricia H Reggio
Journal:  Prog Chem Org Nat Prod       Date:  2017

Review 6.  Cannabinoids and Cytochrome P450 Interactions.

Authors:  Ondřej Zendulka; Gabriela Dovrtělová; Kristýna Nosková; Miroslav Turjap; Alexandra Šulcová; Lumír Hanuš; Jan Juřica
Journal:  Curr Drug Metab       Date:  2016       Impact factor: 3.731

7.  Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.

Authors:  Orrin Devinsky; Anup D Patel; J Helen Cross; Vicente Villanueva; Elaine C Wirrell; Michael Privitera; Sam M Greenwood; Claire Roberts; Daniel Checketts; Kevan E VanLandingham; Sameer M Zuberi
Journal:  N Engl J Med       Date:  2018-05-17       Impact factor: 91.245

Review 8.  An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors.

Authors:  Paula Morales; Patricia H Reggio
Journal:  Cannabis Cannabinoid Res       Date:  2017-10-01

9.  Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.

Authors:  F M Leweke; D Piomelli; F Pahlisch; D Muhl; C W Gerth; C Hoyer; J Klosterkötter; M Hellmich; D Koethe
Journal:  Transl Psychiatry       Date:  2012-03-20       Impact factor: 6.222

10.  Binding and Signaling Studies Disclose a Potential Allosteric Site for Cannabidiol in Cannabinoid CB2 Receptors.

Authors:  Eva Martínez-Pinilla; Katia Varani; Irene Reyes-Resina; Edgar Angelats; Fabrizio Vincenzi; Carlos Ferreiro-Vera; Julen Oyarzabal; Enric I Canela; José L Lanciego; Xavier Nadal; Gemma Navarro; Pier Andrea Borea; Rafael Franco
Journal:  Front Pharmacol       Date:  2017-10-23       Impact factor: 5.810
View more
  8 in total

1.  Emerging Roles of Cannabinoids and Synthetic Cannabinoids in Clinical Experimental Models.

Authors:  Paula Morales; Patricia H Reggio
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Cannabidiol (CBD) Dosing: Plasma Pharmacokinetics and Effects on Accumulation in Skeletal Muscle, Liver and Adipose Tissue.

Authors:  Robert B Child; Mark J Tallon
Journal:  Nutrients       Date:  2022-05-18       Impact factor: 6.706

3.  The antidepressant and anxiolytic effects of cannabinoids in chronic unpredictable stress: a preclinical systematic review and meta-analysis.

Authors:  Noa Reuveni; Cole A Carlson; Sarah Schwartz; Diana Meter; Tyson S Barrett; Sara M Freeman
Journal:  Transl Psychiatry       Date:  2022-05-31       Impact factor: 7.989

Review 4.  The Essential Medicinal Chemistry of Cannabidiol (CBD).

Authors:  Kathryn M Nelson; Jonathan Bisson; Gurpreet Singh; James G Graham; Shao-Nong Chen; J Brent Friesen; Jayme L Dahlin; Matthias Niemitz; Michael A Walters; Guido F Pauli
Journal:  J Med Chem       Date:  2020-09-10       Impact factor: 7.446

5.  Cannabis and Its Permissibility Status.

Authors:  Jawad Alzeer; Khaled Abou Hadeed; Hayriye Basar; Fawzi Al-Razem; Mosaad A Abdel-Wahhab; Yousef Alhamdan
Journal:  Cannabis Cannabinoid Res       Date:  2020-05-12

Review 6.  Cannabidiol and Neurodevelopmental Disorders in Children.

Authors:  Keith A Kwan Cheung; Murray D Mitchell; Helen S Heussler
Journal:  Front Psychiatry       Date:  2021-05-21       Impact factor: 4.157

Review 7.  Can Physical Activity Support the Endocannabinoid System in the Preventive and Therapeutic Approach to Neurological Disorders?

Authors:  Tomasz Charytoniuk; Hubert Zywno; Karolina Konstantynowicz-Nowicka; Klaudia Berk; Wiktor Bzdega; Adrian Chabowski
Journal:  Int J Mol Sci       Date:  2020-06-13       Impact factor: 5.923

Review 8.  Neural Stem Cells and Cannabinoids in the Spotlight as Potential Therapy for Epilepsy.

Authors:  Diogo M Lourenço; Leonor Ribeiro-Rodrigues; Ana M Sebastião; Maria J Diógenes; Sara Xapelli
Journal:  Int J Mol Sci       Date:  2020-10-03       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.